

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Termination of Security Interest

CONVEYING PARTY DATA

Name	Execution Date
Wells Fargo Capital Finance, LLC as successor by merger to Wachovia Capital Finance Corporation (WESTERN)	03/17/2011

RECEIVING PARTY DATA

Name:	Natrol, Inc.
Street Address:	21411 Prairie Street
City:	Chatsworth
State/Country:	CALIFORNIA
Postal Code:	91311

Name:	Medical Research Institute
Street Address:	21411 Prairie Street
City:	Chatsworth
State/Country:	CALIFORNIA
Postal Code:	91311

Name:	Prolab Nutrition, Inc.
Street Address:	21411 Prairie Street
City:	Chatsworth
State/Country:	CALIFORNIA
Postal Code:	91311

PROPERTY NUMBERS Total: 17

Property Type	Number
Patent Number:	6197340
Patent Number:	6572888
Patent Number:	6905707
Patent Number:	6191162

OP \$680.00 6197340

Patent Number:	7118762
Application Number:	11026430
Application Number:	11240790
Application Number:	11693837
Application Number:	10947054
Application Number:	11561821
Application Number:	11199919
Application Number:	11382414
Patent Number:	5770207
Patent Number:	6080410
Patent Number:	4973467
Patent Number:	6113949
Application Number:	11084189

CORRESPONDENCE DATA

Fax Number: (800)914-4240
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 800-713-0710
Email: karen.baker@wolterskluwer.com
Correspondent Name: Karen Baker
Address Line 1: 4400 Easton Common Way - Suite 125
Address Line 2: CT Corporation
Address Line 4: Columbus, OHIO 43219

ATTORNEY DOCKET NUMBER:	F132815
-------------------------	---------

NAME OF SUBMITTER:	Brendan C. Recupero, Counsel to Natrol
--------------------	--

Total Attachments: 6
source=Patent Termination 8107515#page1.tif
source=Patent Termination 8107515#page2.tif
source=Patent Termination 8107515#page3.tif
source=Patent Termination 8107515#page4.tif
source=Patent Termination 8107515#page5.tif
source=Patent Termination 8107515#page6.tif

**TERMINATION AND RELEASE OF PATENT SECURITY
AGREEMENT AND COLLATERAL ASSIGNMENT OF PATENTS**

TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT AND COLLATERAL ASSIGNMENT OF PATENTS, dated as of March 17, 2011, by and between WELLS FARGO CAPITAL FINANCE, LLC, a Delaware limited liability company, as successor by merger to WACHOVIA CAPITAL FINANCE CORPORATION (WESTERN) (the "Agent"), NATROL, INC., a Delaware corporation ("Natrol"), PROLAB NUTRITION, INC., a Connecticut corporation ("Prolab") and Medical Research Institute, a California corporation ("MRI" and together with Natrol and Prolab, the "Companies").

WITNESSETH

WHEREAS, Agent entered into a certain Loan and Security Agreement with the Companies dated August 25, 2006 (as amended, the "Loan Agreement") pursuant to which the parties from time to time party thereto as lenders (each individually, a "Lender" and collectively, the "Lenders") made loans and provided other financial accommodations to the Companies; and

WHEREAS, (i) the Agent, Natrol and Prolab entered into a certain Patent Security Agreement dated August 25, 2006 (the "Patent Security Agreement") and (ii) the Agent, and MRI entered into a Collateral Assignment of Patents dated February 13, 2008 (the "Collateral Assignment of Patents") each for the purpose of securing certain obligations of the Companies to the Agent and the Lenders under the Loan Agreement; and

WHEREAS, pursuant to the Patent Security Agreement and the Collateral Assignment of Patents, the Companies granted to the Agent, for the benefit of the Lenders, a security interest in and lien on, and collaterally assigned to the Agent, for the benefit of the Lenders, all of its patents and patent applications, as well as all its rights under all license agreements to all patents licensed to the Companies thereunder, including without limitation, the patents, patent applications and license rights identified on Exhibit A attached hereto (hereinafter collectively referred to as the "Named Patents"); and

WHEREAS, the Agent has agreed to terminate and release its security interest and all of its right, title and interest in each of the Named Patents as provided herein;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:


1. Release and Assignment. The Agent, in its capacity as agent for the Lenders, hereby terminates and releases, without any recourse, representation or warranty, its security interest in and lien on all of the Companies' Named Patents and the Agent hereby assigns and transfers to the Companies, without any recourse, representation or warranty, all of the Agent's right, title and interest in and to each of the Named Patents effective as of the date set forth above.

2. Acknowledgment and Acceptance. Each of the Companies hereby acknowledge and accept the foregoing release and assignment by the Agent.

3. Counterparts. This Release may be executed in any number of counterparts which shall together constitute one and the same agreement.

IN WITNESS WHEREOF, the Agent and the Companies have executed this Release as of the date set forth above.

WELLS FARGO CAPITAL FINANCE, LLC,
a Delaware limited liability company

By: 
Name: ROBIN VAN HEST
Title: VICE PRESIDENT

NATROL, INC.,
a Delaware corporation

By: 
Name: PATRICIA MCCULLOUGH
Title: PRESIDENT

PROLAB NUTRITION, INC.,
a Connecticut corporation

By: 
Name: PATRICIA MCCULLOUGH
Title: PRESIDENT

MEDICAL RESEARCH INSTITUTE,
a California corporation


By: 
Name: PATRICIA MCCULLOUGH
Title: PRESIDENT



EXHIBIT A
Named Patents

I. Medical Research Institute

Patent Name	Application No.	Registration No.	Filing Date
CONTROLLED RELEASE LIPOIC ACID	09/288,245	6,197,340 B1	4/8/1999
CONTROLLED RELEASE LIPOIC ACID	09/755,890	6,572,888 B2	1/5/2001
CONTROLLED RELEASE ARGININE ALPHA KETOGLUTARATE	10/266,646	6,905,707	8/23/2002
METHOD OF REDUCING SERUM GLUCOSE LEVELS	09/288,253	6,191,162	4/8/1999
CONTROLLED RELEASE LIPOIC ACID	10/412,559	7,118,762	4/11/2003
CONTROLLED RELEASE ARGININE ALPHA KETOGLUTARATE	11/026,430 2005/0106246 A1		12/30/2004
CONTROLLED RELEASE ARGININE ALPHA KETOGLUTARATE	11/240,790 2006/0128806 A1		9/30/2005
ORAL FORMULATION OF LIPID SOLUBLE THIAMINE AND LIPOIC ACID	10/693,837 2004/0259895		10/23/2003
ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE ALPHA-KETOGLUTARATE	10/947,054 2005/0085498 A1		9/21/2004
ORAL FORMULATION OF CREATINE DERIVATIVES AND METHOD OF MANUFACTURING SAME	11/561,821 2007/0071815		11/20/2006
CONTROLLED RELEASE ALPHA LIPOIC ACID FORMULATION WITH AN INOSITOL COMPOUND	11/199,919 2006/00243367		8/8/2005
CONTROLLED RELEASE LIPOIC ACID	11/382,414 2006/0188574		5/9/2006

II. Natrol, Inc. and Prolab Nutrition, Inc.

Patent Name	Application No.	Registration No.	Filing Date
DIETARY SUPPLEMENTS CONTAINING KAVA ROOT EXTRACT, PASSION FLOWER, CHAMOMILE FLOWERS, HOPS, AND SCHIZANDRA FRUIT	08/818,931	5,770,207	3/17/1997
METHOD FOR REDUCING DAILY STRESS AND ANXIETY IN ADULTS	09/102,165	6,080,410	6/22/1998
DIETARY SUPPLEMENT FOR ADULTS	07/421,138	4,973,467	10/13/1989
WEIGHT CONTROL PRODUCT AND METHOD OF TREATING HYPERLIPIDEMIA AND INCREASING VIGOR WITH SAID PRODUCT	09/179,328	6,113,949	10/27/1998
NUTRACEUTICAL FORMULATION OF A COGNITIVE ENHANCEMENT SYSTEM	11/084,189		3/21/2005

JS#302912v1